Zealand chief is pleased with quiet quarter
Internal pipeline activities are progressing well and partner Sanofi has announced good news, so new Zealand Pharma CEO Britt Meelby Jensen is pleased with her first quarter in charge of the biotech company. She also explains the background for a botched partnership with Eli Lilly.
BY STEFAN SINGH KAILAY
The deficit is significant, but that was expected, and the cash base is still solid. Consequently, the most recent quarterly statement from Zealand Pharma did not make any major headlines and new Chief Executive Officer Britt Meelby Jensen is happy to put the lid on a quiet first quarter in charge of a public biotech company.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Zealand CEO: A news-heavy year
For abonnenter
“Cash is king”
For abonnenter
